Immunome (NASDAQ:IMNM) Stock Price Up 5.3%

Immunome, Inc. (NASDAQ:IMNM) was up 5.3% during trading on Tuesday . The company traded as high as $25.42 and last traded at $25.26. Approximately 148,028 shares traded hands during trading, a decline of 78% from the average daily volume of 685,658 shares. The stock had previously closed at $24.00.

Analyst Ratings Changes

A number of research firms have weighed in on IMNM. SVB Leerink initiated coverage on shares of Immunome in a research report on Monday, January 29th. They issued an “outperform” rating and a $30.00 price target for the company. Wedbush upped their target price on shares of Immunome from $12.00 to $19.00 and gave the stock an “outperform” rating in a report on Tuesday, January 23rd. Finally, Leerink Partnrs reissued an “outperform” rating on shares of Immunome in a report on Monday, January 29th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $24.50.

Immunome Stock Performance

The business’s fifty day simple moving average is $22.09 and its 200-day simple moving average is $13.40. The firm has a market capitalization of $1.35 billion, a PE ratio of -13.64 and a beta of 1.67.

Institutional Investors Weigh In On Immunome

A number of hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Immunome by 339.0% during the 4th quarter. Vanguard Group Inc. now owns 1,740,026 shares of the company’s stock worth $18,618,000 after acquiring an additional 1,343,697 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of Immunome by 505.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,051,222 shares of the company’s stock valued at $11,249,000 after purchasing an additional 877,592 shares in the last quarter. Barclays PLC bought a new stake in Immunome in the fourth quarter worth $882,000. Royal Bank of Canada raised its stake in Immunome by 3.2% during the fourth quarter. Royal Bank of Canada now owns 29,484 shares of the company’s stock valued at $315,000 after purchasing an additional 928 shares in the last quarter. Finally, Point72 Asset Management L.P. lifted its position in Immunome by 25.0% during the fourth quarter. Point72 Asset Management L.P. now owns 682,619 shares of the company’s stock valued at $7,304,000 after purchasing an additional 136,700 shares during the last quarter. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

About Immunome

Immunome, Inc operates as a biotechnology company that develops targeted cancer therapies. Its portfolio includes immunotherapies, targeted effectors, radioligand therapies, and antibody drug conjugates (ADCs). The company also offers rapid screening of novel antibodies and targets through memory B cell hybridoma technology.